Biogen Inc. (BIIB) Earnings Call Transcript & Summary

May 1, 2025

NASDAQ US Health Care Biotechnology earnings 64 min

Earnings Call Speaker Segments

Tim Power

executive
#1

Appreciate that, Melinda. Hello everyone, and thanks for joining us for Biogen's Q1 2025 earnings call. On this call, we will be sharing forward-looking statements, and those carry risks plus uncertainties that could lead actual results to differ materially from what we've stated in those forward-looking statements. A full list of risk factors appears in our SEC filings, and we'd encourage you to take a look at them. You can find our earnings release and the other documents tied to our results, along with reconciliations between GAAP and non-GAAP results that we discuss on this call, in the investors' section of biogen.com. The slides we'll be using during the call have also been posted to our website; joining me today are our President and Chief Executive Officer, Chris Viehbacher, Dr. Priya Singhal, who leads our Development organization, and Robin Kramer, our Chief Financial Officer; after some opening comments from us, we'll head into the Q&A session. So that we can get to as many questions as possible, we kindly ask that you keep yourself to one question. Now I'll hand the call over to Chris.

Chris Viehbacher

executive
#2

Thanks, Tim. Morning, everyone. And Robin, let me start by saying welcome — this marks your debut quarter as Biogen's CFO. We're off to a really solid beginning this year, a robust quarter. From where I sit, Biogen genuinely tells the story of two separate firms. One of them is the old MS-focused operation, and that portfolio, as everyone here is aware, has been shrinking steadily. Then there's a fresh Biogen taking shape. If you look at our rare disease unit along with ads, or ZURZUVAE, Leqembi, and Vumerity, what we have is a commercial lineup we're out there actively pushing, and it now accounts for roughly 45% of product revenue. Most of those products have a long growth path ahead; we've discussed this for several years, but I believe it's finally becoming apparent. We're taking these products global. Take Leqembi's approval in Europe — that one matters a great deal to us. We've also secured approval for SKYCLARYS in the U.K. and Brazil. Naturally, our pipeline will serve as the next growth driver. On that front, we're thrilled to receive FDA Fast Track designation for our ASO aimed at BIIB080. That's notable given we haven't even reported phase II results yet, and to me it signals confidence in how significant this prospective new therapy could be for treating Alzheimer's. We've kicked off the phase III TRANSCEND trial of felsartamab in AMR; we've consistently noted our balance sheet is quite strong, and we'll keep adding to the pipeline through outside innovation, patiently and with discipline. We're delighted with the partnership we formed around zoravonersen in Dravet syndrome together with Stoke; that will be a meaningful medicine. We hold rights to it for territories beyond the United States. Now, turning to how these new launches are progressing — Leqembi, I mean, just look at it: $96 million. That's nearly $100 million. We're now in serious product territory. As I mentioned, we've gained marketing authorization in the EU. That matters not only because of the EU's market potential, but because we can now state that this drug has been acknowledged for its significance, its efficacy, and its safety profile by every major regulator globally. That's a meaningful vote of confidence. Once again, this is the first disease-modifying agent ever approved for Alzheimer's. This is completely new ground. I believe that sort of regulatory backing is enormously important. As we're all aware, launching this product has been difficult given the workload it places on treating physicians. We're eagerly anticipating several innovations on the horizon that we believe can ease that burden. To start, one item is already secured from Q1: the green light for IV maintenance, letting us cut how often patients are dosed after 18 months of treatment down to a single administration each month. With any luck, an August approval for the subcutaneous version will make things simpler still for doctors. That carries the possibility of patients administering it themselves at home through an auto injector. Then, during the opening six months of next year, we're anticipating — again, fingers crossed — approval of the subcutaneous form for initiation, something that should sharply lower demand for infusion bed capacity. Separately, and this has nothing to do with Eisai or Biogen — these are stand-alone companies — other firms are working toward approval of biomarker tests, specifically blood-based ones. With luck, at some stage we'll see those blood-based biomarkers replace the requirement for PET scans and/or lumbar punctures. A great many catalysts lie ahead for Leqembi, and with critical mass now behind it, we feel quite encouraged. On top of that, we rolled out a fresh commercialization strategy starting 1st of April. Together with our partners at Eisai, we've invested substantial time re-examining the data, reflecting on what we learned, and adjusted our commercial approach accordingly. For example, one thing we'll pursue this year is beginning direct patient engagement in Alzheimer's; now, moving on to ZURZUVAE, this product keeps performing well. Q1 sales reached $28 million. Since launch, we've managed to treat 10,000 women with PPD. Most of those prescriptions are, in fact, first-line therapy for postpartum depression. Something we discovered along the way: the physician who matters most when treating postpartum depression isn't the psychiatrist — it's the OB-GYN. In Q1, for instance, 80% of our scripts came from OB-GYNs. A key point here is that you're essentially discussing a one-and-done treatment. For this to work commercially, you truly need prescribers to broaden; we did observe that. We managed to grow the number of physicians prescribing it by 20% in Q1. Even more crucial is getting physicians to write repeat prescriptions. One of the most heartening developments is that beyond seeing those repeat prescriptions, I believe as physicians build experience with ZURZUVAE, they also build the confidence to go out and be more proactive in diagnosing postpartum depression. I think a virtuous cycle is genuinely emerging, where positive patient responses are driving greater attention to a disease that, regrettably, has been woefully neglected for far too many women. Excellent progress on ZURZUVAE. Our own field expansion at Biogen is finished, and it's been running since the middle of the quarter. Now, turning to SKYCLARYS, worldwide sales came in at $124 million. That represents a 59% increase compared with the same period last year, plus a 21% gain versus the prior quarter. The IRA did play some role for us. Everyone is aware of the Medicare tax now in effect, and it made a difference. In fact, during this quarter our gross sales within the U.S. climbed at a quicker pace than our net sales. A key aspect of this condition is that it originated in Europe as a genetic disorder. Basically, patients are found wherever the European explorers traveled across the globe. Naturally, Europe holds the largest patient population. We've achieved a great deal of success locating patients there. In my view, it's genuinely simpler to locate them in Europe since they're concentrated in centers, while in the U.S. they're scattered throughout the country. Our U.S. team, even so, has shown real creativity in devising new approaches to pinpoint patient locations and track them down. I recall, years back when Genzyme was acquired, picking up the central marketing lesson of rare disease: it's about finding needles in haystacks. That's precisely what this involves — scanning social media, tracing family trees, and hunting for patients. What's our progress on that front?

Chris Viehbacher

executive
#3

If we can bring up the following slide, what it shows is that patient counts have been rising quite consistently and at a healthy pace; worldwide, roughly 2,400 patients are now receiving therapy. The product has reached 26 markets at this point. One caveat I'd offer is that among those patients, not every one is currently a paying patient; our strategy has involved running early access programs in various countries so that patients can start benefiting from treatment as quickly as feasible; after that, we pursue negotiations market by market. We find the uptake quite encouraging. If you consider how deeply we've penetrated this market, when we compare it against benchmarks, the penetration level is in fact considerably above what a typical analog rare disease launch achieves. In fact, it's roughly in line with how SPINRAZA launched — I wasn't with the company back then, but when we went back and examined the data, that launch stood out as one of the strongest, perhaps the strongest, rare disease product launch ever. We're extremely pleased with how SKYCLARYS is progressing. For us, the approval in Brazil matters a great deal as a market. Brazil has a substantial patient population, and once again, this traces back to where Europeans settled around the globe. I was in Brazil last year and spoke with quite a few physicians there, so I'm confident patients in that country will greet this approval warmly. Turning to the pipeline, I believe we've made tremendous strides in that area too. You've probably heard me remark, I think, repeatedly that when I arrived, the pipeline struck me as carrying extremely high risk. For one thing, it was heavily concentrated in neuroscience. Having just a single therapeutic area is always problematic. Neuroscience also presented complications since the underlying disease biology isn't always well understood. Because these diseases progress slowly, running a phase II study often wasn't possible. You'd move straight into a phase III trial. That means your proof of concept studies end up being enormously expensive phase III efforts. Now, neuroscience remains our identity, and we've had no desire to walk away from it whatsoever. The unmet need there is enormous. Still, we felt a need to build an additional pillar for our company's future growth. Immunology was the obvious direction; we've had a presence in immunology since the company was founded, especially through MS. I'll quote my good friend and former colleague, Elias Zerhouni, who frequently observed, "We describe too many diseases by their symptoms and not by their cause." Once you move into immunology, what truly matters is really the immune pathways. That can steer you toward a wide range of different indications. This is an area Biogen genuinely has strong expertise in. As the chart on the left shows, we've managed to achieve balance here now. We've achieved a solid equilibrium spanning neurology—which for years has been Biogen's cherished stronghold—and, I'd add, immunology, a space where I believe we hold a genuine right to compete. Naturally, alongside that, when you glance at the chart on the right, within immunology one avenue available to you is running a proof of concept. Felsartamab likely stands as the finest illustration of this. It's a perfect sort of product, one where we managed to secure a really robust proof of concept. No clinical trial ever comes with guarantees, as every one of you is aware. When we consider the phase III clinical trials for felsartamab, I think our confidence runs far higher than it does for certain other trials where, once again, we lacked that advantage. If I move to the next chart and you survey our pipeline, the initial point I'd highlight is that five phase III studies are kicking off during this year. That matters from several angles. To start with, plainly, enormous potential sits behind each of those products, and we're entering late-stage development. It signals that our pipeline has matured. Secondly, we're likewise boosting how many shots on goal we take. We don't hinge on merely one or two projects. We'll keep expanding that. A third point I'd raise, I suppose, is that quite a few data readouts lie ahead. As we progress into phase III, we'll also be in position to deliver some significant readouts as early as 2026. That strikes me as a pleasant cadence, one that will help reinforce the ongoing rise of this new Biogen. I'd call it very solid progress, and Priya will elaborate on it further. The final subject I'd like to touch on, I suppose, is the one sitting on everyone's mind—tariffs. It's a fresh topic for all of us; across 35 years in this industry, I've never needed to devote as much time as our team did to tariffs during the first quarter; this ranks among the most tangled areas. I recognize that for investors, it's extremely tangled. I did wish to flag several characteristics of Biogen that, in my view, set us apart from certain peer companies in the sector. Some of you, for example, have relied on the tax rate as a proxy for potential tariff exposure. I'd argue that doing so is actually unsuitable when it comes to Biogen. There are a couple of key reasons. First, if you examine our product sales, 75% of our 2024 U.S. product revenue came from products whose manufacturing operations already sit in the U.S. In truth, Biogen exports a greater amount than we import. Consequently, we likewise pay a great deal of tax. Robin will cover that topic. Our company pays federal as well as state taxes within the United States. Another key structural distinction: roughly 55% of the product revenue we recorded for 2024 was generated by nations beyond America. That is fairly uncommon for our sector. Across most of this industry, you observe that 60%-80% of product revenues originate from the U.S. Biogen is significantly more diversified, and this truly stems from the products in our portfolio. When we consider 2025, clearly, an exemption currently exists. We recognize that the entire tariff landscape shifts every day, making it hard to forecast. What we can at least state is this: even if that exemption disappeared and every tariff announced by the U.S. administration on April 22nd, 2024 were not merely to take effect but additionally be extended to pharmaceuticals, our 2025 financial outlook would remain unaffected. That is partly due to the lengthy supply chains we maintain. It is partly because — and credit here goes to our supply chain team — they have accumulated stockpiles, not only of finished products but also of various ingredients and materials, since, once again, this is an extremely intricate field. Purely from a structural standpoint, we are a company anchored more in the U.S., and have been all along. In fact, we take considerable pride in that.

Chris Viehbacher

executive
#4

With that being said, I'll pass it along to Priya now, and she'll pick up on the R&D conversation from here, including the $20 million to $21 million figure.

Priya Singhal

executive
#5

Thanks, Chris. During this quarter, we achieved meaningful headway in moving forward and broadening our late-stage pipeline of high-conviction programs. Our pipeline, we feel, is set to serve an essential function as we strive to produce durable growth over the long term, fueled by greater momentum in the data we generate. That covers possible major approvals within this year plus registrational data we anticipate beginning in the next year. Over this quarter, we hit important milestones in Alzheimer's, immunology, and rare disease. To begin, as Chris noted, BIIB080, our tau-targeting ASO, was granted Fast Track designation by the FDA in April for Alzheimer's disease. Alzheimer's is a complicated and deadly condition that, in our view, will need several therapeutic strategies to tackle its varied pathologies. BIIB080 takes a differentiated tack toward going after tau, and the Fast Track designation rested on promising phase Ib results, which demonstrated dose-dependent reductions in CSF tau, declines in tau-PET signal, and favorable trends across exploratory cognitive and functional measures. On the immunology side, we kicked off the TRANSCEND phase III trial of felsartamab in AMR. That marks the first among three phase III trials we anticipate launching this year for felsartamab, with further trials in IgAN and PMN expected by the middle of the year. Significantly, we broadened our late-stage rare disease pipeline by acquiring rights to zoravonersen for Dravet syndrome across all territories excluding the United States, Canada, and Mexico. Dravet syndrome is a developmental and epileptic encephalopathy marked by severe recurring seizures and, notably, considerable cognitive and behavioral deficits. Notably, over 90% of patients keep having seizures even when treated with the best anti-seizure medicines available, and no medications are currently approved that meaningfully tackle the underlying cognitive and behavioral elements of the disease. Zoravonersen is an investigational ASO engineered with the potential to, for the first time, address the root cause of Dravet syndrome by boosting NAV1.1 protein production in brain cells. What gives us encouragement about this asset is the phase I/IIa data we've reviewed, particularly regarding cognition and behavior as well as seizures. If you look at the right-hand side of this slide, you'll see why. Scores on the Vineland-3, a commonly used standardized measure of behavioral outcomes, indicate that zoravonersen produced substantial gains across several measures of cognition and behavior. This was first seen within the phase I/IIa study, with continued improvement in the open-label extensions reaching two years. We think these results back the potential for zoravonersen to become the first disease-modifying therapy for Dravet syndrome. We're eager to collaborate with Stoke on moving the phase III EMPEROR study ahead, which we expect to launch within the next few months. We stay focused on pushing forward the standard of care in Alzheimer's, and I think we've achieved considerable progress. Beginning with Leqembi, we're truly thrilled about the recent approval in Europe; we're also pressing ahead with the subcutaneous formulation for both maintenance treatment and initiation to further support patient choice and convenience. Beyond that, the real-world evidence for Leqembi, in our view, keeps reinforcing how pressing it is to treat people who already show symptoms of early AD. We're eager about what blood-based diagnostics might do to knock down obstacles within the healthcare system. Another point I consider essential is that we keep pushing forward on the opening that exists in pre-symptomatic AD. What Clarity AD showed us is that clearing plaque among symptomatic early AD patients produces clinical benefit, and those who are symptomatic with low tau or none at all may be able to gain even more. In our view, AHEAD 3 to 45 is the appropriate trial, built to assess what Leqembi might offer in a genuinely pre-symptomatic group. Past Leqembi, we keep aiming at Alzheimer's disease biology through what could be the next generation of treatments, such as BIIB080 along with innovative delivery technologies. Taking everything together, the strides we're making in Alzheimer's give me encouragement, and I think our position is strong when it comes to steering where treatment options go next. Turning back to the pre-proof of concept pipeline, I once more feel enthusiasm about how far we've come in restoring this portion of the pipeline. A robust scientific rationale guides our investment in these programs, and we take a disciplined, data-driven approach to choices as we seek to construct a lasting pipeline featuring a strong pre-POC set of programs. Over this quarter, we achieved meaningful movement here, among them finishing enrollment in the phase II trial of our LRRK2 inhibitor for idiopathic Parkinson's disease alongside Denali. Staying true to our method of following the science, these phase II results, anticipated next year, will give us clarity regarding what path might lie ahead toward phase III. We'll keep up this way of working as we strive to expand the pipeline by bringing additional assets into early-stage development, whether they come from inside our organization or from outside innovation sources. Having said that, I'd like to pass the call to Robin now for the financial update.

Robin Kramer

executive
#6

Thank you, Priya. It's a pleasure to be on my first earnings call after moving into the CFO position. First, I want to express my appreciation to the members of the investment community I've had the chance to talk with during these initial months as CFO, and I look forward to engaging with many additional ones of you soon. To kick things off, I'd like to share a handful of highlights regarding our financial results for the first quarter. Keep in mind that the comparisons I'm making are against the first quarter of 2024, unless I say otherwise. First quarter total revenue came to $2.4 billion, representing 6% growth year-over-year, helped partly by the timing of shipments for SPINRAZA and corporate partner revenue. Roughly $200 million of revenue in the first quarter came from our four launch products, which is a 22% rise quarter-over-quarter and more than double the year-over-year figure. Non-GAAP diluted EPS for the first quarter was $3.02, a decline of 18%. That figure reflects the $165 million upfront payment tied to the Stoke transaction, which reduced EPS by about $0.95 during the quarter. Excluding that charge, non-GAAP diluted EPS in the first quarter would have reached $3.97, an 8% increase year-over-year; during the first quarter, free cash flow generated was $222 million, which includes the $165 million upfront amount paid to Stoke. We closed the quarter with $2.6 billion in cash. In a moment, I'll give an update on our full-year guidance; first, let me offer some remarks about revenue and commercial trends in the first quarter. Beginning with our MS franchise, global product revenue fell 11% year-over-year, mainly because of competition. This reflected the effects of a biosimilar for Tysabri in Europe along with generic competition for Tecfidera worldwide. Generics have begun launching in certain European countries, including France and the Netherlands. Although we will keep defending our IP aggressively, we do anticipate additional effects from Tecfidera generics in Europe during this year. One positive for MS in Q1 was Vumerity, which saw demand rise, and Vumerity continues to hold the top spot among branded oral therapies. On SPINRAZA, we remain encouraged by consistent demand worldwide, including 4% growth year-over-year in the U.S. In the first quarter, SPINRAZA revenue outside the U.S. gained from a one-time VAT refund and the timing of shipments in certain markets, which combined provided a benefit of roughly $26 million compared with Q1 of 2024. As I noted earlier, our four launch products combined brought Biogen $200 million of revenue in the first quarter, a 22% increase quarter-over-quarter and more than double the prior-year period; we keep seeing steady sequential growth for Leqembi, with global in-market sales of approximately $96 million booked by Eisai in the first quarter, up about 11% sequentially from the fourth quarter of 2024. SKYCLARYS worldwide sales came in at $124 million, which marks a 21% rise from quarter to quarter compared with Q4 of 2024, fueled by ongoing geographic growth beyond the United States. U.S. revenue for SKYCLARYS reached $69 million, held back by anticipated Medicare discount effects, though demand growth partly made up for that. Demand gains for each product keep pushing both ZURZUVAE and SKYCLARYS upward sequentially. When it comes to corporate partner revenue, the first-quarter bump stemmed from the scheduling of specific batch commitments tied to our contract manufacturing operations, a portion of which related to Leqembi batches; our view remains that corporate partner revenue should be about level when you compare the entirety of 2025 against the entirety of 2024. Because of scheduled maintenance work and how batch releases fall, we anticipate very little corporate partner revenue in Q4. Now I'll shift to a handful of points on expenses. Increased lower margin contract manufacturing revenue weighed on first-quarter non-GAAP cost of sales. Non-GAAP core operating expense — that's R&D plus SG&A — fell 1% versus the same period last year, since gains from our R&D prioritization and fit for growth efforts gave us room to take on added spending tied to our growing and advancing development pipeline, plus our product launches. Non-GAAP operating income carried roughly $201 million in acquired in-process R&D charges, among them the $165 million upfront payment tied to the Stoke transaction, which delivered an impact to EPS of approximately 95%. Had that $165 million upfront payment been excluded, non-GAAP operating income would have landed at $748 million, a 7% gain versus a year earlier. Keep in mind that we, like our peers, must show upfront and milestone charges within GAAP and non-GAAP operating results. Starting with this quarter, we'll separate acquired in-process R&D — covering upfronts and milestones — into its own line item on our P&L, matching what many peers do. Our view is that this gives clearer visibility into our core R&D work and business development work; we intend to share a schedule of anticipated charges for every quarter before our earnings calls so modeling is easier; next I want to give a quick update on our balance sheet; free cash flow for the first quarter totaled $222 million, which factors in that $165 million upfront payment to Stoke mentioned earlier. We closed the quarter holding $2.6 billion in cash along with roughly $3.7 billion in net debt, and we think our balance sheet stays solid, which lets us keep putting money into both internal and external growth opportunities. Moving to guidance, we're glad that our anticipated underlying business outlook for the year hasn't shifted in any material way; we're revising our full-year EPS guidance to capture the roughly 95% impact from the Stoke transaction, plus a $0.20 earnings tailwind stemming from foreign exchange effects due to a weaker U.S. dollar. Our full-year 2025 non-GAAP diluted earnings per share is now projected to fall between $14.50-$15.50. We still anticipate that total revenue for 2025 will fall by a mid-single-digit percentage, mainly because of a steeper decline in our MS business; our launch products should deliver sequential revenue growth, yet we expect the absolute drop in MS revenue to outpace that growth in 2025. Just to remind everyone, we anticipate a possible biosimilar entry for Tysabri in the U.S., which we think might happen at some point during the fourth quarter of this year. As I said a few minutes ago, generics for Tecfidera have begun entering Europe, and although we will keep defending our IP aggressively, we do anticipate additional effects from generics in Europe this year. As I mentioned earlier, we believe corporate partner revenue will be approximately flat when comparing full year 2025 with full year 2024. Because of planned maintenance activities and the timing of batch releases, we anticipate minimal corporate partner revenue in Q4. We believe we remain on track to achieve the $1 billion of gross savings and $800 million of net savings under our fit for growth initiative. As the slide shows, many of our guidance considerations are unchanged from when we guided for the year back in February. I'd also point you to our press release for other important guidance assumptions. One subject that greatly interests many investors is how tariffs might affect our business. Biogen currently does not anticipate a material impact in 2025 from potential tariffs as announced by the U.S. administration on April 2nd, 2025, even if the exemption for pharmaceuticals were removed. That view rests on both a significant portion of U.S. revenue coming from products with manufacturing operations in the United States, as well as our current global inventory positions. Our guidance range also takes into account potential retaliatory tariffs from China as announced. That said, the U.S. and international tariff landscape remains uncertain, and our guidance does not contemplate any new tariffs that may be announced in the future. I'll also note that when excluding one-time tax impacts, our tax rate is broadly a function of our business mix and therefore is not a good proxy for estimating potential tariff impacts. Biogen's effective tax rate reflects our U.S. market revenues being almost entirely taxable in the U.S. at the full federal plus state tax rates; we also generate a relatively high percentage of our revenue outside the U.S., which is taxable in those markets and in the U.S. under the GILTI regime. We will keep monitoring and analyzing the current and future US and reciprocal tariff landscape as it evolves. I'll now pass the call over to Chris for some closing comments.

Chris Viehbacher

executive
#7

Thanks, Robin. So once more, when it comes to where Biogen is headed, the answer really lies in our pipeline. Four additional phase restarts are underway, on top of the phase restart that has already happened in AMR. Three clinical trial readouts are on the way. Three regulatory decisions are on the way. Another point I want to make is that during this first quarter, we carried out a significant restructuring of research, and I'm genuinely enthusiastic about what we're building there. Our industry leans far too heavily on late-stage business development. The place where collaborations give you the most bang for the buck is actually in the preclinical stage, and our target is to sign 4 to 5 new research collaborations during this year. Speaking just of research, Biogen has a reputation for breakthrough medicines. In fact, each of the 4 products we brought to market in 2023 and 2024 is a first-in-class, first-ever disease-modifying agent. We pursue some of the diseases that are hardest to treat. A challenge that comes with being breakthrough is that you're working in diseases where a great deal of the investment committee isn't already doing much research. Take AMR, antibody-mediated rejection, as an example — there's essentially no treatment available for it today. Something I think we'd like to do is take a deeper dive into a number of these diseases and pipeline assets, not because we intend to present new data, but simply to ask, "Alright, what does the competitive landscape look like? What gives Biogen the right to win here? What does the patient journey look like? What will it truly take to move the needle on one of these diseases? How will the reimbursement landscape shape up? What does the epidemiology tell us?" Looking at AMR, for instance, I believe this represents a massive opportunity for Biogen. We observed 80% resolution of AMR in phase II trials; our confidence in that is high. Naturally, many people are focused on IgAN. What would it take for real interest in IgAN? I devoted an entire day with our West Coast hub focused solely on Felsartamab. There's an enormous amount happening there. Even something like the fact that all CD38s are not created equally. What are they like? We'd love to invite anyone who's interested to attend some of these thematic seminars. The first one takes place on June 11th. Hopefully it will be the first in the series. The whole point is to be educational and to go deeper. We'll have some of our top internal experts here covering all of these subjects to answer any and all questions; with that, Tim, I'll hand it back to you for Q&A.

Tim Power

executive
#8

Thanks, Chris. Melinda, can we go to our first question, please?

Brian Abrahams

analyst
#9

Good morning, and thank you for taking my question. I want to congratulate you on the recent European approval of Leqembi. Could you walk us through how you expect the launch to unfold in that region, and what your perspective is on the reimbursement process and how willing payers might be to engage? Thanks.

Chris Viehbacher

executive
#10

Thank you, Brian. I think this is certainly going to take considerable time. The lengthy approval process itself signals that a great deal of deliberation has gone into it. When you're bringing a first-in-class disease-modifying therapy to market, one key point is that you aren't taking budget away from any existing product. Products like these represent additional spending on top of what nations already allocate for healthcare. Sometimes it's simpler to introduce something that's essentially a copycat, one that just takes budget away from an existing drug; clearly, this represents a large opportunity in Europe. Compared with the United States, Europe's population is older. A great many people there qualify as potential patients; together with our partner Eisai, we'll pursue that opportunity one market at a time. I also believe Leqembi has been through the wringer. What I mean is that its efficacy, its safety, and its economic value have all been thoroughly scrutinized. The EMA, as everyone is aware, factors in certain elements related to economic consequences. In certain respects, this thorough scrutiny from every nation in the European Union, incidentally, ought to actually work in our favor when we move into the reimbursement stage, since everything has been completely scrutinized and completely assessed. Some time will still be required, in my view. We'll approach certain nations and obviously bring the product to market more quickly there, which is typically how things work across Europe.

Tim Power

executive
#11

Thanks, Chris. Let's go to the next question, please.

Evan Seigerman

analyst
#12

Hello, everyone. I really appreciate you taking my question. I'd like to revisit Leqembi, though this time regarding the subcutaneous version. Could you perhaps walk us through how the possibility of administering it at home might speed up sales within the United States? We are observing decent uptake, but I believe that could genuinely push things forward even more, and maybe discuss a few of the obstacles that need to be cleared to truly achieve full penetration there. Thanks.

Chris Viehbacher

executive
#13

Sure. To start, subcutaneous is for maintenance. These patients have been receiving infusions every two weeks for 18 months now. For the commercial side, I see two dimensions. The first is that we're concentrating on ensuring physicians and patients grasp why therapy needs to continue. On that front, we have long-term extension data, and we've shown that even at 36 months following treatment, patients continue to fare better while on treatment compared with stopping it. Then there's building out the entire maintenance market. These patients also tend to be older, and reaching infusion centers isn't always simple. Naturally, once-monthly dosing makes things simpler for them. Our perspective is that a patient-friendly mode of administration such as subcutaneous will prove more effective as a long-term chronic therapy. As an initial step, subcutaneous genuinely assists in establishing and prolonging the treatment life of a patient during maintenance. After that, obviously, during the initiation phase, it will be worth watching. In big urban centers, I suspect some physicians might prefer to stay with infusion, at least through the first few months of therapy, since those are scheduled alongside the MRIs for monitoring ARIA, and then switch to subcutaneous. I can picture that in more rural areas, where reaching infusion centers isn't as convenient for patients, subcutaneous could be used right from the start. It will probably vary somewhat depending on where a patient is located, yet without a doubt this is, once again, a reduction of the physician's workload. It's a substantial burden to consider the PET scans or the lumbar punctures, to go and negotiate for infusion bed access, which are frequently viewed as belonging to the oncologist. Purely from a caregiver's perspective of transporting the patient to the infusion center, I believe they'll welcome this too, since it can be done at home. To my mind, this is an enabler for the patient, and for the physician as well.

Tim Power

executive
#14

Melinda, can we go to the next question, please?

Salveen Richter

analyst
#15

Thanks. Morning, everyone. To build on what Evan asked, could you share your perspective regarding how Leqembi will be adopted and expand going forward — not just from subcutaneous maintenance dosing arriving in the back half of the year, but also from the in vitro diagnostic that Fujirebio is bringing, which ought to reach the market too? Thanks.

Chris Viehbacher

executive
#16

Sure, our knowledge regarding that diagnostic is fairly limited. Getting a diagnostic cleared follows a pathway that, clearly, differs from that of a drug. How reimbursement works is likewise not the same. I do believe the Alzheimer's Association's recent report made clear how important early diagnosis is. As I see it, one of the problems in Alzheimer's has been that the majority of patients are in fact going to their primary care physician, and it may take a considerable amount of time before that physician can work out whether this is simply normal aging, whether it is another dementia form, or whether it is Alzheimer's. It's possible for 2 or 3 years to pass, and at times even more, before a neurologist referral leads to an Alzheimer's diagnosis. Now, something else that Alzheimer's report emphasized is that there is genuine enthusiasm for beginning treatment sooner, and that reaching a patient earlier, before excessive neuronal damage or death has occurred, produces better results. I believe substantial work lies ahead to truly establish those diagnostics. The upside, as I see it, comes in 2 ways. First, we hopefully can start patients on treatment when their disease is at a far earlier stage. That's our belief, and studies are of course underway to actually obtain the evidence for it. Even the data we shared at CTAD in 2023 on low-tau patients, which serves as a surrogate for early-stage patients, showed that 60% of patients were stable at 6 months. In fact, 70% were stable at 6 months, and 60% actually demonstrated some degree of improvement. I think blood-based diagnostics will matter enormously. Once again, we must wait and see what stage those companies have reached in the regulatory process. Could we take the next question, please?

Tim Anderson

analyst
#17

Thank you; regarding Leqembi, how do you see the market splitting between your drug and Lilly's Kisunla? Since clearly, there's a huge gap when it comes to commercial positioning around finite dosing. I'm curious who will ultimately prevail in that fight. Chris, you responded to an earlier question by beginning with the topic of getting physicians to keep patients on treatment. Your drug has now been available for nearly two and a half years. Are you in fact observing some prescribers discontinue therapy after a certain period, operating on the belief that once plaque is eliminated, drugs no longer need to be administered?

Chris Viehbacher

executive
#18

Yeah. To start, I'd argue that the real debut of this offering was September 2023, since that's the point when we secured complete approval. CMS reimbursement was in place. As a matter of fact, clarity on the reimbursement question for PET scans didn't arrive until roughly November of that same year. In my view, we remain quite early within that rollout period. Regarding your comparison with donanemab, it varies from one physician to another. There will likely be some people who gravitate toward the notion that this has a defined endpoint. At the same time, based on what came out of ADPD most recently, when a maintenance indication exists and the data begins coming in, it becomes clear that clearing the plaque doesn't mean the job is finished, since plaque can come back and cause possible harm. Clearly, a good deal of education will be needed to make the case for staying with treatment. Ultimately, the decision will mostly rest with the doctor and the patient. Some individuals will find donanemab to be the appropriate option. That choice hinges on how frail they are, how old they are, and if they live in a rural or an urban area.

Tim Power

executive
#19

Can we go to the next question, please, Melinda?

Chris Schott

analyst
#20

Oh, that's great. I really appreciate you taking the question. I'd like to hear a little more about your current thinking when it comes to business development — specifically around how big the deals are and what kinds of scope you're looking at. The market has clearly been quite volatile out there. I'm curious whether that has shifted your perspective in any way, or changed the sorts of opportunities that could be available to Biogen. Thank you.

Chris Viehbacher

executive
#21

Yeah, thanks for asking that. I'd say there has been a change, maybe even over the last, let's call it, 4 to 6 weeks, in a few respects. Valuation is one piece of it, but your focus remains on finding the right asset. What I believe is different now is that many healthcare investors are under significant pressure from their LPs. They're seeking liquidity, in my view. We've also seen plenty of companies that haven't really wanted to act much, since valuations remain low; on top of that, we're finding many companies are having a hard time securing financing. If you're on the acquiring side, I'd say it may be somewhat easier to at least get into a conversation. Even when it comes to collaboration, one thing I expect we'll see — and this ties into what we're doing with early research collaborations — is that companies will be in a position to supply some of the funding as venture capital and other funding sources dry up for other companies. There are opportunities in that. You still need a tremendous amount of patience and discipline to work through things and identify companies that fit well together. I genuinely believe Biogen is well positioned. Something I take particular pride in is our West Coast hub, which is basically the high bio team. We've managed to keep virtually everyone on that high bio team. Jane brought in our head of immunology, who came over from BMS and is based out there on the West Coast, and we're continuing to build that team out. Because of our own biotech roots, I think Biogen is a company that understands how to form collaborations and can serve as a trusted partner here. I do see this as an opportunity. As I said, we review a lot of things, but even in conditions like these, you still have to remain disciplined.

Tim Power

executive
#22

Thanks, Chris. Can we go to the next question, please?

Michael Yee

analyst
#23

Thank you. Morning, everyone. I'd like to direct a question to Priya regarding the early AHEAD 3 to 45 trial. I'm aware you've provided guidance pointing to a 2028 data readout. Your rival has likewise given guidance for a readout, though I believe there's a general expectation theirs might arrive sooner. Could you perhaps address one or two aspects concerning how you're positioned relative to that trial, and specifically what would make you feel highly assured that it will succeed and/or produce a readout? Since I'm aware an interim analysis exists, but I'll presume you won't be acting on it. Thank you.

Priya Singhal

executive
#24

Yes. Thank you, Mike. Let me begin by noting that through Clarity AD, we demonstrated Leqembi removes plaque, and that this translates into clinical benefit. Regarding the pre-symptomatic Alzheimer's disease space, it represents a broad spectrum. Our view is that AHEAD 3 to 45 is genuinely set up to deliver a thorough comprehension and assessment of the ways Leqembi may safeguard cognition throughout the entire range of pre-symptomatic AD. That's because we're investigating it through two concurrent studies. The initial one, AHEAD 3, involves roughly 400 participants. According to the inclusion criteria, they have 20 to 40 centiloids of amyloid. The second study covers those above 40 centiloids, corresponding to the AHEAD 45 amyloid levels. In that one, we're examining whether cognitive decline can be prevented. AHEAD 3 asks whether we can halt amyloid buildup, using amyloid PET as its primary endpoint. AHEAD 45 focuses on preventing cognitive decline. We employ a highly sensitive clinical measure known as the PAC-5, alongside amyloid and tau PET. By comparison, I'd note that TRAILBLAZER-ALZ 3 is essentially assessing whether donanemab is able to slow clinical progression within a mixed population. That's determined by their baseline CDR global scores. Roughly 55% are truly presymptomatic, while 45% of enrolled patients are symptomatic. These trials are in fact fairly distinct. We're examining the complete range of presymptomatic patients with differing amyloid levels. We anticipate completing full enrollment. We anticipate a 2028 readout; we always keep open the possibility of reviewing data sooner and such; we aren't making any statement about that at present; our focus is on a 2028 readout.

Chris Viehbacher

executive
#25

Sure. From a business standpoint, I believe the AHEAD study is going to address far more of what doctors are actually going to want to know. If you're dealing with presymptomatic patients, these are people who are healthy apart from that, correct? At that stage, the calculation of risk versus benefit shifts. ARIA is linked to both of these products. You'll need to provide an answer regarding the trade-off between risk and benefit when treating earlier, and at what amount of amyloid burden. I believe that will prove valuable, since blood-based diagnostics can indicate whether amyloid is present, but they won't reveal the quantity. Eventually, you reach a point where someone is 55, their blood test came back positive, and they'll be referred for a PET scan to determine the extent of their amyloid. Suppose you're at 50. Do you take a watch-and-wait approach, or do you go ahead and treat? Without having conducted research examining the entire range of amyloid burden, I doubt physicians will feel at ease about treating. I genuinely believe AHEAD 3 to 45 will end up being truly landmark studies in Alzheimer's.

Tim Power

executive
#26

Can we go to the next question, please, Melinda?

Mike DiFiore

analyst
#27

Hello, Mike DiFiore here, filling in for Umer. We really appreciate you fielding our question. Once more, I'd like to focus on Leqembi. During Q1 — the second complete quarter since its launch — Lilly's drug generated roughly $21 million in revenue. That's a bit ahead of where Leqembi stood at the equivalent stage. So my question is this: have Biogen and Eisai essentially cleared a path for Lilly when it comes to getting healthcare infrastructure opened up? And maybe you could address whatever competitive forces are now in play, given that you're about 18 months into the launch? Thank you.

Chris Viehbacher

executive
#28

Yes would probably be my answer. Obviously, an enormous amount of effort has gone in, especially from the IDNs, to sort through every treatment pathway, protocol, and treatment regimen that's required. At this point, what we're dealing with is lecanemab versus donanemab in those respects. Like I mentioned before, there will be situations where doctors consider both products. Which one gets initiated, I think, is the question. Switching isn't something I believe we're observing at all here. It truly comes down to which one you begin on and then remain on. The larger issue, I'd say, is whether we can all together expand the market. That, honestly, matters most. Trying to simply battle it out over share in a market that's still fairly small isn't really what we want to do. Plenty of patients exist out there, and we aren't yet providing full service to those who are suffering. The more centers we can bring online and the better the education, the more beneficial that is for patients and, in fact, for both companies.

Tim Power

executive
#29

Chris, please move us along to the following one. Also, somewhere in this range we're looking at 12,000 to 13,000.

Terence Flynn

analyst
#30

Thanks a lot for fielding the questions. Clearly, quite a bit of attention has landed on the FDA with the new administration in place. I'm aware you said a few things regarding your Dravet program advancing to a phase III. Could you speak at a high level, first, about how things stand with the FDA and whether the review teams have shifted in any way? And second, when it comes to certain rare diseases, do you expect this FDA to move very quickly and to look more kindly on the industry, perhaps when it comes to surrogate endpoints? Thank you.

Priya Singhal

executive
#31

Yes, thank you. Broadly speaking, I'll offer a high-level remark: judging by our review meetings, our interactions, and the requests we've made, nothing much appears to have shifted at a high level. Right now, our engagements are proceeding as planned. On Dravet syndrome, clearly the data we reviewed during diligence, which I also discussed today, struck us as very compelling. There are multiple dimensions to it. To begin with, even though this was a small open-label trial, what mattered, I think, was that these patients were receiving standard of care. Sadly, Dravet carries a heavy disease burden, and these patients experience numerous seizures, at times 7 to 10 weekly. They take multiple medications, anti-seizure medications; as a matter of fact, we observed what zoravonersen did when added on top of standard of care. What we observed was an 87% seizure reduction on top of background standard of care, complete standard of care; that held up, durability-wise, at roughly 76% when you look out six months. Those data mattered. The second part of what you asked concerns the fact that Stoke had already been in touch with FDA, Europe, and Japan. We have regulator input, which we've assessed thoroughly; we have alignment on the approach and design for the phase III EMPEROR study. We stay fairly confident that this is the correct trial to run. We stay encouraged about where we stand in our engagement, not just with the FDA, but with global regulators, and that the design is suitable to truly deliver that answer on what we hope will be a disease-modifying therapy impact in this population.

Chris Viehbacher

executive
#32

Regarding your larger question, at Biogen specifically, we honestly haven't encountered any holdups when dealing with the FDA as of now. Personally, I take encouragement from certain recent remarks made by the new commissioner concerning ultra rare conditions, and about surrogate markers, plus ensuring patients receive medicines sooner. He appears, in my view, more keen on bringing innovation into parts of the process — for instance, his comments about cutting back on animal testing and employing AI. A great deal of transformation is definitely happening at the FDA, and we are monitoring it closely. Clearly, a few important leaders have departed, and there's been a decrease in personnel; according to them, at least from Biogen's perspective, no negative impact has appeared thus far. Maybe certain fresh viewpoints from the new Commissioner, Makary, might in fact prove beneficial for us.

Tim Power

executive
#33

Appreciate that, Chris. I realize this morning is packed, so perhaps we can fit in a final question. Melinda, let's take our last one, please.

Geoff Meacham

analyst
#34

Excellent. Good morning, everybody. I appreciate the inquiry. This one is for Chris or Robin, regarding production. If you look back at the initial forecasts for Alzheimer's, Biogen has traditionally held quite a bit of capacity within the United States. So here's what I'm asking: given that we're seeing additional biopharma firms declare intentions to move capacity onshore, do you two think about your own capacity or your resources in a different way? I'm curious whether a near-term chance exists to bring in a partner, something that isn't reflected in the model. Naturally, everything hinges on how much excess you happen to have. Thanks.

Robin Kramer

executive
#35

Yes. Across the two facilities, we maintain a solid balance involving manufacturing for our own products and manufacturing for partners.

Tim Power

executive
#36

All right, that's all the time we have. Thanks so much, everyone, for being here — I really do appreciate it. Should anything else come up for you later today, please don't hesitate to get in touch with the IR team. Thanks again.

Operator

operator
#37

That wraps up the call for today. Thanks for joining us. You're free to hang up now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.